Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Hereditary Angioedema (Aug 2017)

Posted by Matt Breese on Aug 23, 2017

Find me on:

According to our recent payer coverage analysis for hereditary angioedema treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A complex mix of pharmacy and medical benefit coverage exists for HAE treatments. Products are generally covered with a PA and there are minimal step restrictions, with the exception of one or two treatments.

mmit-reality-check-hae-3q2017.png

Source: MMIT data as of Q3 2017

Trends:  Recent news related to HAE treatments highlights some key trends in this therapeutic area. A handful of hereditary angioedema launches reveals the shift in drug development from manufacturers. Novel therapies incite increased prophylaxis utilization. Additionally, the recent launch of an HAE treatment for pediatric patients provides some additional options for prescribers.

To read the full Reality Check on hereditary angioedema with key findings on clinical characteristics, HAE drug market access and payer coverage, please click on the button below: 

MMIT-RC_Thumbnail_1-1.png


View Reality Check

 

Topics: Specialty, Market Access, Branding & Marketing